Welcome to our dedicated page for Baxter Intl news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter Intl stock.
Baxter International Inc. (NYSE: BAX) is a global medtech company whose news flow reflects its focus on connected care technologies, medical devices and advanced injectable therapies. On this page, readers can follow company announcements that illustrate how Baxter’s products and partnerships intersect with hospital operations, nursing workflows and patient safety.
Recent Baxter news highlights the launch of the Dynamo Series smart stretcher, designed for emergency departments, perioperative environments and patient transport services. Baxter reports that the Dynamo Series is intended to reduce the need for patient transfers, support a range of procedures in-stretcher, and incorporate technologies such as SafeView+ visual cues, bed exit alarms and optional connectivity to EMRs and nurse call systems to help prevent patient falls and support care teams.
Other updates include a multi-year strategic partnership with MUSC Health focused on integrating connected care technologies at the bedside. Baxter and MUSC Health describe objectives such as standardizing and simplifying bedside technologies, reducing documentation time, streamlining communication, improving nurse satisfaction and retention, and using real-time insights and advanced monitoring to enhance quality and safety outcomes.
Baxter also issues news on its infusion therapy portfolio, such as real-world data presented with The University of Texas Medical Branch on the Spectrum IQ large volume infusion pumps. These analyses examine how smart pump integration with electronic medical records may affect patient safety alerts, infusion programming time and clinician workload.
In addition, investors can find announcements on capital allocation decisions, including tender offers for senior notes, new note issuances and dividend declarations, as well as philanthropic news from the Baxter Foundation, such as grants to support STEM education through the Baxter Center for Science Education. Bookmark this page to access Baxter’s latest product, partnership, financial and community impact news in one place.
Baxter International (NYSE:BAX) has announced its participation in the 7th Annual Evercore HealthCONx Conference. Joel Grade, the company's chief financial officer, will deliver a presentation on Thursday, December 5, 2024, at 9:10 a.m. Eastern Time. The presentation will be accessible via live webcast on www.baxter.com and will remain available for replay until Tuesday, June 3, 2025.
Baxter International (NYSE:BAX) has announced its participation in the upcoming Jefferies London Healthcare Conference. The company's Chief Financial Officer, Joel Grade, will deliver a presentation on Wednesday, November 20, 2024, at 11:00 a.m. GMT. The presentation will be accessible through a live webcast on www.baxter.com, with replay availability extending through Monday, May 19, 2025.
Baxter International (NYSE:BAX) has announced its participation in the Stifel 2024 Healthcare Conference. Joel Grade, the company's chief financial officer, will deliver a presentation on Monday, November 18, 2024, at 8:35 a.m. Eastern Time. The presentation will be available via live webcast on www.baxter.com and can be accessed for replay through May 17, 2025.
Baxter International (NYSE:BAX) has declared a quarterly cash dividend of $0.17 per share of common stock, payable on Jan. 2, 2025, to stockholders of record as of Nov. 29, 2024. The indicated annual dividend rate is $0.68 per share. This new quarterly dividend rate is set in anticipation of the Kidney Care business segment divestiture to Carlyle, expected to close in late 2024 or early 2025. The dividend targets a payout ratio of approximately 25% of adjusted net income, aligning with peer companies. Baxter maintains its 93-year history of consistent dividend payments while balancing business reinvestment with shareholder returns.
Baxter (BAX) reported Q3 2024 total sales of $3.85 billion, with continuing operations sales of $2.70 billion increasing 4% on both reported and constant currency basis. The company achieved total U.S. GAAP diluted EPS of $0.27 and adjusted EPS of $0.80, exceeding previous guidance. Hurricane Helene significantly impacted the North Cove facility, though production has restarted on the highest-throughput IV solutions line. The company announced the pending sale of its Kidney Care business to Carlyle for $3.80 billion, expected to close in late 2024 or early 2025. Due to hurricane impact, Baxter adjusted its full-year 2024 outlook, expecting total company sales growth of 1-2% and adjusted EPS of $2.90-$2.94.
Baxter International (NYSE:BAX) announced its participation in the upcoming UBS Global Healthcare Conference. Chief Financial Officer Joel Grade will deliver a presentation on Wednesday, November 13, 2024, at 1:15 p.m. Pacific Time. The presentation will be accessible through a live webcast on www.baxter.com, with replay availability extending through Monday, May 12, 2025.
Baxter International Inc. (NYSE:BAX), a global medtech leader, has announced it will host a conference call to discuss its third-quarter 2024 financial results on Friday, November 8, 2024 at 7:30 a.m. Central Time. Interested participants can pre-register for the call through a provided link to receive call information. The conference call will also be webcast and accessible via Baxter's website at www.baxter.com. Baxter has noted that the call will be recorded and is copyrighted material, prohibiting unauthorized recording or rebroadcasting without the company's permission.
Baxter International Inc. (NYSE:BAX) has provided an update on the impact of Hurricane Helene on its North Cove facility in Marion, N.C. The facility is currently closed for production due to flooding, and the company is working closely with various government agencies to assess the damage and resume operations. Key points:
1. Baxter is implementing measures to minimize supply disruptions, including managing inventory and using a protective allocation process.
2. The company will leverage its global manufacturing network to mitigate potential supply impacts.
3. The Baxter International Foundation has committed $1.5 million in donations for recovery efforts and is matching employee donations 2:1.
4. Baxter anticipates a negative impact on its financial results due to the disruption and plans to provide an update in its third quarter earnings announcement.
Baxter International Inc. (NYSE:BAX) has launched The Vest Advanced Pulmonary Experience (APX) System, its next-generation airway clearance system, at the North American Cystic Fibrosis Conference. This system, designed for adults and children with certain chronic lung conditions and retained secretions, features enhanced comfort and patient-centered improvements based on clinician and patient input.
Key features include:
- A streamlined, lightweight garment with wicking fabric and Velcro closure
- New garment colors and designs for adults and children
- User-friendly touch screen navigation
- Smaller and lighter control unit with carrying case
- Optional CARE Connex Program for ongoing support
The Vest APX System uses High Frequency Chest Wall Oscillation (HFCWO) technology to help dislodge and mobilize mucus in the lungs. Baxter received FDA 510(k) clearance for the system earlier this year, and it will be available to order this fall.
Baxter International Inc. (NYSE:BAX), a global medtech leader, has appointed Jeffrey (Jay) A. Craig to its board of directors. Craig, former executive chair and CEO of Meritor , will serve on Baxter's Audit Committee. His appointment is effective immediately, bringing the total number of directors to 12. Baxter's chair, president and CEO, José (Joe) E. Almeida, expressed excitement about Craig's addition, highlighting his broad-based business leadership and operational expertise as a former CEO, CFO, COO, and public company auditor. This appointment is expected to complement the current board's expertise with Craig's deep financial experience and public company board background.